IXICO plc announced that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under 5 years and is worth in excess of £1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7 GBX | -1.75% | -1.75% | -44.00% |
Jun. 19 | Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study | MT |
Jun. 19 | AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.00% | 4.4M | |
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces New Pharma Client Contract Valued in Excess of £1 Million for A Study of A Parkinsonian Disorder